Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 2009

View Archived Issues

Genentech and Array BioPharma report novel Akt-1 protein kinase inhibitors

Oligomer-guanidine conjugates active against pain claimed by Nektar Therapeutics

GABA-A alpha5 receptor ligands for cognitive disorders presented by Roche

Simvastatin not beneficial in aneurysmal subarachnoid hemorrhage

Apixaban thromboprophylaxis and bleeding risk compared to those of enoxaparin

Biotie Therapies describes active metabolite of anti-inflammatory agent ELB-353

BMS reports development of its PPARalpha-selective dual agonist BMS-759509

Neurotune obtains approval for phase II dimiracetam trial in neuropathic pain

Advaxis to collaborate with City of Hope for leukemia and lymphoma vaccine

ActoGeniX receives grant to develop AG-013 for treatment of oral mucositis

FDA grants accelerated approval of Hiberix vaccine for Hib booster dose

11beta-HSD1 inhibitors for metabolic syndrome reported by Wyeth

Pfizer tests mGluR2 positive allosteric modulators in psychosis models

Glenmark discloses novel VR1 antagonists for the treatment of pain

Biovitrum AB reports the invention of 11beta-HSD1 inhibitors for glaucoma

Novel c-Met inhibitors designed at sanofi-aventis

Aska Pharmaceuticals describes novel PPAR activators

NIH develops novel PDE4 inhibitors for respiratory disorders

Quest launches influenza A H1N1 test in the U.S.

New indication for Helixate FS approved by FDA

Bristol-Myers Squibb reports second quarter 2009 results

Health Canada grants approval to Anika's Monovisc for osteoarthritis of the knee

Cel-Sci expands flu virus research program

The Medicines Company withdraws European MAA for oritavancin in cSSSI

Phase II trial of NeoFuse in lumbar spinal fusion surgery cleared by FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...